

Sanket S Dhruva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7503628/publications.pdf>

Version: 2024-02-01

98
papers

2,260
citations

304602

22
h-index

254106

43
g-index

103
all docs

103
docs citations

103
times ranked

2982
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical studies sponsored by digital health companies participating in the FDA's Precertification Pilot Program: A cross-sectional analysis. <i>Clinical Trials</i> , 2022, 19, 119-122.	0.7	2
2	Resource Utilization Following Coronary Computed Tomographic Angiography and Stress Echocardiography in Patients Presenting to the Emergency Department With Chest Pain. <i>American Journal of Cardiology</i> , 2022, 163, 8-12.	0.7	2
3	Coverage of Transvenous Pulmonary Embolectomy " Medicare's Missed Opportunity for Evidence Generation. <i>New England Journal of Medicine</i> , 2022, 386, 904-906.	13.9	3
4	Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019. <i>JAMA Internal Medicine</i> , 2022, 182, 185.	2.6	16
5	A 510(k) ancestry of robotic surgical systems. <i>International Journal of Surgery</i> , 2022, 98, 106229.	1.1	4
6	Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	1
7	Strategies to Manage Drugs and Devices Approved Based on Limited Evidence: Results of a Modified Delphi Panel. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1307-1314.	2.3	2
8	US Food and Drug Administration "Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019. <i>JAMA Internal Medicine</i> , 2022, 182, 556.	2.6	5
9	Evaluation of cardiovascular implantable electronic device leads post implant: ElectroPhysiology Predictable And Sustainable Implementation Of National Registries (EP PASSION). <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, , 1.	0.6	4
10	Letter by Dhruva and Redberg Regarding Article, "Amplatz Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial" <i>Circulation</i> , 2022, 145, e845-e846.	1.6	0
11	Factors associated with remote monitoring adherence for cardiovascular implantable electronic devices. <i>Heart Rhythm</i> , 2022, 19, 1499-1507.	0.3	11
12	Medical Device User Fee Reauthorization " Back to Basics or Looking Ahead?. <i>New England Journal of Medicine</i> , 2022, 387, 196-199.	13.9	2
13	Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2516-2525.	1.2	34
14	Endoscopic transmission of carbapenem-resistant Enterobacteriaceae: implications for U.S. Food and Drug Administration approval and postmarket surveillance of endoscopic devices. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 231-238.	0.5	2
15	Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2035064.	2.8	9
16	GLASS(Y) Half-Full. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007690.	0.9	0
17	Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>JAMA Network Open</i> , 2021, 4, e2037748.	2.8	54
18	Media Portrayals of Extracorporeal Membrane Oxygenation. <i>JAMA Internal Medicine</i> , 2021, 181, 394.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Medicare's New Device-Coverage Pathway "Breakthrough or Breakdown?". <i>New England Journal of Medicine</i> , 2021, 384, e43.	13.9	9
20	Changing FDA Approval Standards: Ethical Implications for Patient Consent. <i>Journal of General Internal Medicine</i> , 2021, 36, 3212-3214.	1.3	10
21	Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020. <i>JAMA Internal Medicine</i> , 2021, 181, 1409.	2.6	4
22	Outcomes-Driven Clinical Phenotyping in Cardiogenic Shock using a Mixture of Experts. , 2021, , .		1
23	Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 2241-2250.	2.2	14
24	Physical activity, patient-reported symptoms, and clinical events: Insights into postprocedural recovery from personal digital devices. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, 212-221.	0.5	2
25	Reporting of Death in US Food and Drug Administration Medical Device Adverse Event Reports in Categories Other Than Death. <i>JAMA Internal Medicine</i> , 2021, 181, 1217.	2.6	10
26	Characteristics, interventions and outcomes of patients with valvular heart disease hospitalised in China: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e052946.	0.8	8
27	Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center. <i>BMJ Surgery, Interventions, and Health Technologies</i> , 2021, 3, e000089.	0.6	4
28	Heart Watch Study: protocol for a pragmatic randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e054550.	0.8	1
29	Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics. <i>Journal of General Internal Medicine</i> , 2020, 35, 1928-1930.	1.3	5
30	The Art of the Deal: Negotiating Consult Conflict. <i>American Journal of Medicine</i> , 2020, 133, 889-891.	0.6	1
31	Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shock"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 303.	3.8	8
32	Early experience with the FDA's Breakthrough Devices program. <i>Nature Biotechnology</i> , 2020, 38, 933-938.	9.4	20
33	Mandatory Registration and Results Reporting of Real-World Evidence Studies of FDA-Regulated Medical Products. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2609-2611.	1.4	5
34	Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019. <i>JAMA Internal Medicine</i> , 2020, 180, 1701.	2.6	15
35	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 734.	3.8	260
36	A Successful but Underused Strategy for Reducing Low-Value Care: Stop Paying for It. <i>JAMA Internal Medicine</i> , 2020, 180, 532.	2.6	3

#	ARTICLE	IF	CITATIONS
37	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. <i>Journal of the American Heart Association</i> , 2020, 9, e013606.	1.6	10
38	2019 Update on Pediatric Medical Overuse. <i>JAMA Pediatrics</i> , 2020, 174, 375.	3.3	14
39	Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. <i>Npj Digital Medicine</i> , 2020, 3, 60.	5.7	51
40	Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials—a brave new world. <i>Clinical Trials</i> , 2020, 17, 243-246.	0.7	2
41	Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender Individuals. <i>LGBT Health</i> , 2020, 7, 137-145.	1.8	10
42	Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies. <i>Journal of General Internal Medicine</i> , 2019, 34, 2319-2321.	1.3	4
43	Moving From Substantial Equivalence to Substantial Improvement for 510(k) Devices. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 927.	3.8	19
44	Controversies in Diagnostic Imaging of Patients With Suspected Stable and Acute Chest Pain Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1254-1278.	2.3	6
45	Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016. <i>JAMA Network Open</i> , 2019, 2, e1913298.	2.8	7
46	Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence. <i>JAMA Network Open</i> , 2019, 2, e1912869.	2.8	167
47	Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study. <i>BMC Medicine</i> , 2019, 17, 188.	2.3	8
48	2019 Update on Medical Overuse. <i>JAMA Internal Medicine</i> , 2019, 179, 1568.	2.6	60
49	Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates. <i>Circulation</i> , 2019, 140, 1227-1230.	1.6	11
50	Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis. <i>BMC Medicine</i> , 2019, 17, 117.	2.3	14
51	Evaluation of technologies approved for supplemental payments in the United States. <i>BMJ: British Medical Journal</i> , 2019, 365, l2190.	2.4	8
52	Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments. <i>JAMA Network Open</i> , 2019, 2, e193410.	2.8	15
53	2018 Update on Pediatric Medical Overuse. <i>JAMA Pediatrics</i> , 2019, 173, 379.	3.3	18
54	Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017. <i>Journal of General Internal Medicine</i> , 2019, 34, 518-520.	1.3	5

#	ARTICLE	IF	CITATIONS
55	Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1201-1217.	0.5	0
56	2018 Update on Medical Overuse. <i>JAMA Internal Medicine</i> , 2019, 179, 240.	2.6	40
57	Medical Overuse of Prostate-Specific Antigen Testing and Overprescription of Antibiotics—Reply. <i>JAMA Internal Medicine</i> , 2018, 178, 432.	2.6	0
58	2017 Update on Pediatric Medical Overuse. <i>JAMA Pediatrics</i> , 2018, 172, 482.	3.3	32
59	2017 Update on Medical Overuse. <i>JAMA Internal Medicine</i> , 2018, 178, 110.	2.6	61
60	New and incremental FDA black box warnings from 2008 to 2015. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 117-123.	1.0	21
61	Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016. <i>Medicine (United States)</i> , 2018, 97, e12715.	0.4	8
62	Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. <i>BMJ Open</i> , 2018, 8, e021685.	0.8	3
63	Enhancing the prediction of acute kidney injury risk after percutaneous coronary intervention using machine learning techniques: A retrospective cohort study. <i>PLoS Medicine</i> , 2018, 15, e1002703.	3.9	91
64	Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1230-1238.	0.5	14
65	Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program. <i>JAMA Internal Medicine</i> , 2018, 178, 1418.	2.6	5
66	Fulfilling the Promise of Unique Device Identifiers. <i>Annals of Internal Medicine</i> , 2018, 169, 183.	2.0	18
67	Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. <i>BMJ: British Medical Journal</i> , 2018, 361, k2031.	2.4	52
68	Age of Data at the Time of Publication of Contemporary Clinical Trials. <i>JAMA Network Open</i> , 2018, 1, e181065.	2.8	23
69	Real-World Evidence: Promise and Peril For Medical Product Evaluation. <i>P and T</i> , 2018, 43, 464-472.	1.0	19
70	Letter by Dhruva and Redberg Regarding Article, “Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program.” <i>Circulation</i> , 2017, 135, e20-e21.	1.6	0
71	Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent) <i>Tj ETQq1 1.0.784314 rgBT /Cv</i>	1.3	15
72	Real-World Data on Heart Failure Readmission Reduction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2366-2368.	1.2	11

#	ARTICLE	IF	CITATIONS
73	Transcatheter Aortic Valve Replacement in Younger Individuals. JAMA Internal Medicine, 2017, 177, 159.	2.6	9
74	Update on Pediatric Overuse. Pediatrics, 2017, 139, .	1.0	40
75	Coronary Computed Tomography Angiography vs Functional Stress Testing for Patients With Suspected Coronary Artery Disease. JAMA Internal Medicine, 2017, 177, 1623.	2.6	116
76	Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices. JAMA Internal Medicine, 2017, 177, 1390.	2.6	12
77	Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements. JAMA - Journal of the American Medical Association, 2017, 318, 619.	3.8	20
78	Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results. Journal of the American Heart Association, 2017, 6, .	1.6	16
79	The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 1066-1076.	0.5	22
80	Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015. Annals of Internal Medicine, 2017, 167, 895.	2.0	19
81	Association between FDA black box warnings and Medicare formulary coverage changes. American Journal of Managed Care, 2017, 23, e310-e315.	0.8	3
82	The Core Value of Cost-Effectiveness Analysesâ—. Journal of the American College of Cardiology, 2016, 67, 39-41.	1.2	6
83	Championing Effectiveness Before Cost-Effectiveness â—. JACC: Heart Failure, 2016, 4, 376-379.	1.9	13
84	For the Patient with âœLow-risk Chest Painâ€”How Low Is Low?. Academic Radiology, 2016, 23, 1587-1591.	1.3	5
85	2016 Update on Medical Overuse. JAMA Internal Medicine, 2016, 176, 1687.	2.6	92
86	Application of Medicareâ€™s New Technology Add-on Payment Program for Blinatumomab. JAMA Oncology, 2016, 2, 165.	3.4	3
87	Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. BMJ, The, 2015, 350, h2613-h2613.	3.0	30
88	Revisiting Essure â€” Toward Safe and Effective Sterilization. New England Journal of Medicine, 2015, 373, e17.	13.9	59
89	Update on Medical Practices That Should Be Questioned in 2015. JAMA Internal Medicine, 2015, 175, 1960.	2.6	33
90	Gender Bias in Studies for FDA Premarket Approval of Cardiovascular Devices. Current Cardiovascular Risk Reports, 2014, 8, 1.	0.8	2

#	ARTICLE	IF	CITATIONS
91	FDA regulation of cardiovascular devices and opportunities for improvement. Journal of Interventional Cardiac Electrophysiology, 2013, 36, 99-105.	0.6	10
92	Medical Device Regulation: Time to Improve Performance. PLoS Medicine, 2012, 9, e1001277.	3.9	12
93	Evaluating Sex Differences in Medical Device Clinical Trials. JAMA - Journal of the American Medical Association, 2012, 307, 1145.	3.8	28
94	Gender Bias in Studies for Food and Drug Administration Premarket Approval of Cardiovascular Devices. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 165-171.	0.9	71
95	Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies. Archives of Internal Medicine, 2011, 171, 534-9.	4.3	9
96	Accelerated Approval and Possible Withdrawal of Midodrine. JAMA - Journal of the American Medical Association, 2010, 304, 2172.	3.8	36
97	CMS's Landmark Decision on CT Colonography "Examining the Relevant Data. New England Journal of Medicine, 2009, 360, 2699-2701.	13.9	58
98	Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices. JAMA - Journal of the American Medical Association, 2009, 302, 2679.	3.8	157